271 related articles for article (PubMed ID: 25711494)
1. Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome.
Huang R; Zheng J; Li S; Tao T; Ma J; Liu W
Acta Obstet Gynecol Scand; 2015 May; 94(5):494-500. PubMed ID: 25711494
[TBL] [Abstract][Full Text] [Related]
2. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.
Lerchbaum E; Schwetz V; Rabe T; Giuliani A; Obermayer-Pietsch B
PLoS One; 2014; 9(10):e108263. PubMed ID: 25310562
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
7. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran.
Tehrani FR; Rashidi H; Khomami MB; Tohidi M; Azizi F
Reprod Biol Endocrinol; 2014 Sep; 12():89. PubMed ID: 25224635
[TBL] [Abstract][Full Text] [Related]
9. The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.
He H; Feng J; Zhang S; Wang Y; Li J; Gao J; Cong J; Gong Y; Wu X
Front Endocrinol (Lausanne); 2021; 12():773781. PubMed ID: 35069437
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiological study of clinical characteristics of Chinese Han ethnic women with polycystic ovary syndrome].
Zhao JL; Chen ZJ; Zhao LX; Geng L; Wang S; Gao SS; Zhang P; Liu S; Zhou FR
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):375-9. PubMed ID: 16831357
[TBL] [Abstract][Full Text] [Related]
11. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype.
Engmann L; Jin S; Sun F; Legro RS; Polotsky AJ; Hansen KR; Coutifaris C; Diamond MP; Eisenberg E; Zhang H; Santoro N;
Am J Obstet Gynecol; 2017 May; 216(5):493.e1-493.e13. PubMed ID: 28104402
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
[TBL] [Abstract][Full Text] [Related]
13. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.
O'Reilly MW; Taylor AE; Crabtree NJ; Hughes BA; Capper F; Crowley RK; Stewart PM; Tomlinson JW; Arlt W
J Clin Endocrinol Metab; 2014 Mar; 99(3):1027-36. PubMed ID: 24423344
[TBL] [Abstract][Full Text] [Related]
14. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population.
Mansour A; Mirahmad M; Mohajeri-Tehrani MR; Jamalizadeh M; Hosseinimousa S; Rashidi F; Asili P; Sajjadi-Jazi SM
Sci Rep; 2023 Jun; 13(1):10269. PubMed ID: 37355686
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovaries in Hirsute women with normal menses.
Carmina E; Lobo RA
Am J Med; 2001 Dec; 111(8):602-6. PubMed ID: 11755502
[TBL] [Abstract][Full Text] [Related]
17. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
18. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
19. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
[TBL] [Abstract][Full Text] [Related]
20. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
